Genfit (GNFT.PA) Stock Price

Genfit Price

Euronext·CLOSED
13.44EUR+0.30 (+2.26 %)
Market closed

Over the last 19 years Genfit grew revenue by 9.3% annually, reaching 70.94 M EUR. Earnings per share have declined at 8.1% per year over the last 19 years. For Genfit, the net margin of 2.1% is up versus -1,304.7% a few years ago. The consensus 12-month price target for Genfit is 9.18 EUR, about 31.7% below where the stock trades today. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 341% above its 52-week low.

Genfit stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Genfit over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genfit stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genfit's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Genfit Stock Price History
DateGenfit Price
7/24/202613.44 EUR
7/23/202613.14 EUR
7/22/202613.22 EUR
7/21/202614.06 EUR
7/20/202613.56 EUR
7/17/202612.56 EUR
7/16/202613.00 EUR
7/15/202613.60 EUR
7/14/202613.00 EUR
7/13/202613.44 EUR
7/10/202613.74 EUR
7/9/202613.78 EUR
7/8/202613.90 EUR
7/7/202613.46 EUR
7/6/202613.40 EUR
7/3/202612.46 EUR
7/2/202610.58 EUR
7/1/202610.30 EUR
6/30/202610.60 EUR
6/29/202610.56 EUR
6/26/202610.16 EUR
6/25/20269.57 EUR
6/24/202610.46 EUR
6/23/202611.02 EUR
6/22/202610.72 EUR
6/19/202610.28 EUR
6/18/202610.42 EUR
6/17/20269.61 EUR
6/16/20269.65 EUR
6/15/20269.28 EUR
6/12/20269.06 EUR
6/11/20268.63 EUR
6/10/20268.41 EUR
6/9/20268.48 EUR
6/8/20268.77 EUR
6/5/20268.77 EUR
6/4/20269.10 EUR
6/3/20268.55 EUR
6/2/20268.51 EUR
6/1/20268.57 EUR
5/29/20268.80 EUR
5/28/20268.72 EUR
5/27/20268.57 EUR
5/26/20268.53 EUR
5/25/20268.66 EUR
5/22/20268.52 EUR
5/21/20268.53 EUR
5/20/20268.57 EUR
5/19/20268.50 EUR
5/18/20268.42 EUR
5/15/20268.60 EUR
5/14/20268.88 EUR
5/13/20268.90 EUR
5/12/20268.76 EUR
5/11/20268.86 EUR
5/8/20268.52 EUR
5/7/20268.40 EUR
5/6/20268.43 EUR
5/5/20268.14 EUR
5/4/20268.18 EUR
4/30/20268.08 EUR
4/29/20267.87 EUR
4/28/20268.09 EUR
4/27/20268.13 EUR
4/24/20268.18 EUR
4/23/20268.20 EUR
4/22/20268.85 EUR
4/21/20268.90 EUR
4/20/20269.12 EUR
4/17/20269.18 EUR
4/16/20269.08 EUR
4/15/20269.35 EUR
4/14/20269.30 EUR
4/13/20268.80 EUR
4/10/20268.68 EUR
4/9/20267.98 EUR
4/8/20267.96 EUR
4/7/20267.45 EUR
4/2/20268.63 EUR
4/1/20268.63 EUR
3/31/20268.48 EUR
3/30/20268.31 EUR
3/27/20268.31 EUR
3/26/20268.50 EUR
3/25/20268.56 EUR
3/24/20268.43 EUR
3/23/20269.06 EUR
3/20/20268.73 EUR
3/19/20269.10 EUR
3/18/20268.80 EUR
3/17/20268.77 EUR
3/16/20268.58 EUR
3/13/20268.49 EUR
3/12/20268.70 EUR
3/11/20268.97 EUR
3/10/20269.36 EUR
3/9/20268.90 EUR
3/6/20268.52 EUR
3/5/20268.74 EUR
3/4/20268.64 EUR
3/3/20268.48 EUR
3/2/20268.89 EUR
2/27/20268.98 EUR
2/26/20268.85 EUR
2/25/20269.08 EUR
2/24/20269.09 EUR
2/23/20268.71 EUR
2/20/20267.88 EUR
2/19/20268.14 EUR
2/18/20267.86 EUR
2/17/20268.02 EUR
2/16/20267.64 EUR
2/13/20267.13 EUR
2/12/20267.13 EUR
2/11/20266.72 EUR
2/10/20266.52 EUR
2/9/20266.25 EUR
2/6/20266.09 EUR
2/5/20266.32 EUR
2/4/20266.18 EUR
2/3/20266.43 EUR
2/2/20265.82 EUR
1/30/20265.60 EUR
1/29/20265.65 EUR
1/28/20265.70 EUR
1/27/20265.64 EUR
1/26/20265.50 EUR
1/23/20265.55 EUR
1/22/20265.55 EUR
1/21/20265.26 EUR
1/20/20265.22 EUR
1/19/20265.28 EUR
1/16/20265.26 EUR
1/15/20265.41 EUR
1/14/20265.43 EUR
1/13/20265.28 EUR
1/12/20265.28 EUR
1/9/20265.31 EUR
1/8/20265.25 EUR
1/7/20265.36 EUR
1/6/20265.30 EUR
1/5/20265.18 EUR
1/2/20265.25 EUR
12/31/20255.26 EUR
12/30/20255.32 EUR
12/29/20255.29 EUR
12/24/20255.15 EUR
12/23/20255.13 EUR
12/22/20255.09 EUR
12/19/20254.97 EUR
12/18/20255.01 EUR
12/17/20254.98 EUR
12/16/20255.03 EUR
12/15/20255.00 EUR
12/12/20255.10 EUR
12/11/20255.20 EUR
12/10/20254.95 EUR
12/9/20254.75 EUR
12/8/20254.66 EUR
12/5/20254.65 EUR
12/4/20254.85 EUR
12/3/20255.05 EUR
12/2/20254.76 EUR
12/1/20254.50 EUR
11/28/20254.46 EUR
11/27/20254.27 EUR
11/26/20254.01 EUR
11/25/20253.96 EUR
11/24/20253.81 EUR
11/21/20253.73 EUR
11/20/20253.72 EUR
11/19/20253.88 EUR
11/18/20253.78 EUR
11/17/20253.82 EUR
11/14/20253.76 EUR
11/13/20253.72 EUR
11/12/20253.79 EUR
11/11/20253.67 EUR
11/10/20253.63 EUR
11/7/20253.42 EUR
11/6/20253.50 EUR
11/5/20253.52 EUR
11/4/20253.59 EUR
11/3/20253.55 EUR
10/31/20253.62 EUR
10/30/20253.64 EUR
10/29/20253.66 EUR
10/28/20253.57 EUR
10/27/20253.67 EUR
10/24/20253.73 EUR
10/23/20253.69 EUR
10/22/20253.80 EUR
10/21/20253.71 EUR
10/20/20253.63 EUR
10/17/20253.70 EUR
10/16/20253.64 EUR
10/15/20253.66 EUR
10/14/20253.63 EUR
10/13/20253.68 EUR
10/10/20253.75 EUR
10/9/20253.84 EUR
10/8/20253.45 EUR
10/7/20253.43 EUR
10/6/20253.42 EUR
10/3/20253.50 EUR
10/2/20253.50 EUR
10/1/20253.37 EUR
9/30/20253.27 EUR
9/29/20253.16 EUR
9/26/20253.13 EUR
9/25/20253.05 EUR
9/24/20253.11 EUR
9/23/20253.13 EUR
9/22/20253.29 EUR
9/19/20253.61 EUR
9/18/20253.65 EUR
9/17/20253.59 EUR
9/16/20253.62 EUR
9/15/20253.62 EUR
9/12/20253.60 EUR
9/11/20253.61 EUR
9/10/20253.54 EUR
9/9/20253.54 EUR
9/8/20253.45 EUR
9/5/20253.44 EUR
9/4/20253.40 EUR
9/3/20253.37 EUR
9/2/20253.36 EUR
9/1/20253.46 EUR
8/29/20253.45 EUR
8/28/20253.48 EUR
8/27/20253.53 EUR
8/26/20253.53 EUR
8/25/20253.64 EUR
8/22/20253.79 EUR
8/21/20253.74 EUR
8/20/20253.73 EUR
8/19/20253.85 EUR
8/18/20253.94 EUR
8/15/20253.57 EUR
8/14/20253.61 EUR
8/13/20253.54 EUR
8/12/20253.36 EUR
8/11/20253.34 EUR
8/8/20253.33 EUR
8/7/20253.34 EUR
8/6/20253.31 EUR
8/5/20253.44 EUR
8/4/20253.35 EUR
8/1/20253.37 EUR
7/31/20253.48 EUR
7/30/20253.52 EUR
7/29/20253.58 EUR
7/28/20253.62 EUR
Access this data via the Eulerpool API
Get Free API Key

Genfit Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
26.57 M EUR
-27.31 M EUR
-23.72 M EUR
Jan 1, 2023
38.18 M EUR
-26.66 M EUR
-28.89 M EUR
Jan 1, 2024
70.94 M EUR
3.23 M EUR
1.51 M EUR
Jan 1, 2025 (e)
56.83 M EUR
13.46 M EUR
-20.76 M EUR
Jan 1, 2026 (e)
59.18 M EUR
4.37 M EUR
509,450.20 EUR
Jan 1, 2027 (e)
72.61 M EUR
-459,000.00 EUR
-15.16 M EUR
Jan 1, 2028 (e)
59.87 M EUR
-25.64 M EUR
-14.73 M EUR
Jan 1, 2029 (e)
71.02 M EUR
-5.93 M EUR
0.00 EUR

Genfit Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 26, 2026, 3:26 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
2016201720182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
6.006.007.0040.007.0085.0026.0038.0070.0056.0059.0072.0059.0071.00118.00184.00
50.00–16.67471.43-82.501,114.29-69.4146.1584.21-20.005.3622.03-18.0620.3466.2055.93
66.6766.6771.4395.0071.4398.8292.3194.7497.1497.1497.1497.1497.1497.1497.1497.14
4.004.005.0038.005.0084.0024.0036.0068.0054.4057.3169.9457.3168.97114.63178.74
-34.00-56.00-69.00-57.00-77.0032.00-27.00-26.003.0013.004.00–-25.00-5.0048.00–
-566.67-933.33-985.71-142.50-1,100.0037.65-103.85-68.424.2923.216.78–-42.37-7.0440.68–
-33.00-55.00-79.00-65.00-101.0067.00-23.00-28.001.00-20.00–-15.00-14.00–––
94.1266.6743.64-17.7255.38-166.34-134.3321.74-103.57-2,100.00––-6.67–––
26.8531.1731.1736.9938.8655.6149.6749.7049.9549.9549.9549.9549.9549.9549.9549.95
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Genfit generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genfit retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genfit's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Genfit has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genfit's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Genfit stock margins

The Genfit margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genfit. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genfit.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
73.21 %
-999.08 %
-1,304.73 %
Jan 1, 2021
98.28 %
37.68 %
78.59 %
Jan 1, 2022
92.00 %
-102.78 %
-89.28 %
Jan 1, 2023
94.32 %
-69.84 %
-75.69 %
Jan 1, 2024
97.11 %
4.55 %
2.12 %
Jan 1, 2025 (e)
97.11 %
23.69 %
-36.53 %
Jan 1, 2026 (e)
97.11 %
7.38 %
0.86 %
Jan 1, 2027 (e)
97.11 %
-0.63 %
-20.87 %

Genfit Stock Revenue, EBIT, Earnings per Share

The Genfit earnings per share therefore indicates how much revenue Genfit has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.20 EUR
-1.99 EUR
-2.60 EUR
Jan 1, 2021
1.54 EUR
0.58 EUR
1.21 EUR
Jan 1, 2022
0.53 EUR
-0.55 EUR
-0.48 EUR
Jan 1, 2023
0.77 EUR
-0.54 EUR
-0.58 EUR
Jan 1, 2024
1.42 EUR
0.06 EUR
0.03 EUR
Jan 1, 2025 (e)
1.14 EUR
0.27 EUR
-0.42 EUR
Jan 1, 2026 (e)
1.18 EUR
0.09 EUR
0.01 EUR
Jan 1, 2027 (e)
1.45 EUR
-0.01 EUR
-0.30 EUR

Genfit business model & stock analysis

Genfit SA is a French company specializing in the development of therapies for the treatment of liver diseases, specifically non-alcoholic steatohepatitis (NASH). The company was founded in 1999 and is headquartered in Loos, France.

Genfit SWOT Analysis

Strengths

Genfit SA has several strengths that contribute to its competitive advantage in the market. These strengths include:

  • Advanced Research and Development Capabilities
  • Strong Intellectual Property Portfolio
  • Experienced Management Team
  • Strategic Partnerships and Collaborations
  • Robust Pipeline of Drug Candidates
  • Global Presence and Market Reach

Weaknesses

Despite its strengths, Genfit SA also faces certain weaknesses that can hinder its growth and performance. These weaknesses include:

  • Limited Financial Resources
  • Reliance on a Few Key Drug Candidates
  • Dependency on External Funding
  • Heavy Competition in the Pharmaceutical Industry
  • Regulatory and Compliance Risks

Opportunities

Genfit SA can leverage various opportunities in the market to drive its future success. These opportunities include:

  • Rising Prevalence of Liver Diseases Globally
  • Increasing Demand for Innovative Therapies
  • Expansion into Emerging Markets
  • Advancements in Technology and Research
  • Strategic Acquisitions and Partnerships
  • Growing Adoption of Personalized Medicine

Threats

Genfit SA must also be aware of potential threats that can affect its business and market position. These threats include:

  • Intense Competition from Established Players
  • Stringent Regulatory Approvals and Delays
  • Uncertainty in Healthcare Reforms and Policies
  • Market Volatility and Economic Downturns
  • Emergence of Alternative Treatment Options
  • Intellectual Property Infringement

Genfit Segments

Genfit Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Genfit historical P/E ratio, EBIT multiple, and P/S ratio

Genfit annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Genfit shares outstanding

The number of shares of Genfit was 49.95 M in 2025. This indicates how many shares Genfit is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
38.86 M Stocks
Jan 1, 2021
55.61 M Stocks
Jan 1, 2022
49.67 M Stocks
Jan 1, 2023
49.70 M Stocks
Jan 1, 2024
49.95 M Stocks
Jan 1, 2025 (e)
49.95 M Stocks
Jan 1, 2026 (e)
49.95 M Stocks
Jan 1, 2027 (e)
49.95 M Stocks

Current Genfit forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.45 %
Buy91.67 % (11)
Hold8.33 % (1)
Sell0.00 % (0)
12M Price Target
9.18
Last Price
13.44
Currency
EUR
12M Return Potential
-31.70 %
LTM Return
0 %

Genfit Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
4/11/20240.33EUR49.92 MEUR2024 Q4

EESG©

Eulerpool ESG Scorecard© for the Genfit stock

74/100
82
Environment
99
Social
39
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees62.893
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Genfit shareholder structure

% Name
7.97908%
Ipsen Pharma SAS
Ipsen Pharma SAS
5.89083%
683 Capital Management LLC
683 Capital Management LLC
3.78131%
Biotech Avenir SAS
Biotech Avenir SAS
1.30391%
Université Lille 2
Université Lille 2
0.24059%
CPR Asset Management
CPR Asset Management
0.12013%
Sunny Asset Management
Sunny Asset Management

Genfit Executives and Management Board

PP

Mr. Pascal Prigent

(57)

Chief Executive Officer

Compensation681,945.00 EUR
JM

Mr. Jean-Francois Mouney

(69)

Chairman of the Board of Directors · since 1999

Compensation382,684.00 EUR
DH

Dr. Dean Hum

(62)

Chief Scientific Officer · since 2022

Compensation140,597.00 EUR
EB

Mr. Eric Baclet

(65)

Independent Vice-Chairman of the Board of Directors

Compensation68,416.00 EUR
CL

Dr. Catherine Larue

(69)

Independent Director · since 2011

Compensation50,140.00 EUR

Genfit Supply Chain

Genfit Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#Name1M3M6M1Y2YTrend
1
Terns Pharmaceuticals
Supplier
0.17
0.43
0.43
-0.27
—
2
Laboratory Corp
Supplier
0.23
0.67
0.58
0.20
-0.59

Frequently asked questions about Genfit

Genfit SA's business model focuses on developing and commercializing innovative therapeutic solutions for patients with metabolic and liver-related diseases. The company primarily specializes in non-alcoholic steatohepatitis (NASH), which is a progressive disease of the liver. Genfit SA's business strategy involves conducting research and development activities, clinical trials, and obtaining regulatory approvals. By creating a pipeline of potential drug candidates, Genfit SA aims to address the unmet medical needs of individuals suffering from NASH and related conditions. The company's ultimate goal is to provide effective treatment options and improve the overall quality of life for patients in this specific market.

All fundamentals and in-depth analysis of Genfit

Our stock analysis for Genfit stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genfit. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Genfit Stock
Genfit Revenue→
Genfit Stock
Genfit Net Income→
Genfit Stock
Genfit P/E→
Genfit Stock
Genfit P/S→
Genfit Stock
Genfit EBIT→
Genfit Stock
Genfit Dividend→
Genfit Stock
Genfit Directors Dealings→
Genfit Stock
Genfit Stocks→
Genfit Stock
Genfit Market capitalization→
Genfit Stock
Genfit Debt→
Genfit Stock
Genfit Liabilities→
Genfit Stock
Genfit Equity→
Genfit Stock
Genfit AAQS→
Genfit Stock
Genfit Employees→
Genfit Stock
Genfit ROE→
Genfit Stock
Genfit ROA→
Genfit Stock
Genfit ROCE→
Genfit Stock
Genfit News→
Genfit Stock
Genfit Analyst Price Targets→

Health Stocks

GeninusGenexineGenmab ASGenex PharmaceuticalGenMont BiotechGenetics Generation AdvancementGennex LaboratoriesGenetic TechnologiesGenocea BiosciencesGenetic SignaturesGenolutionGeneSystem CoAll Stocks A–Z →